New skin device shows promise for wrinkle and pigment reduction

NCT ID NCT06645366

Completed Symptom relief Sponsor: BTL Industries Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed trial tested the BTL-785F device on 39 healthy adults over 30 who wanted better skin on their face and neck. Participants received three treatments, each lasting 20–60 minutes, spaced 2–6 weeks apart. The goal was to see if the device could improve skin texture, reduce wrinkles, pigmentation, and laxity, as measured by photos and patient satisfaction.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BTL-785F device (a skin treatment device using a specialized tip and applicator)
What this could lead to: If it works, this could offer a non-invasive option for improving skin texture and reducing wrinkles, pigmentation, and laxity on the face and neck.
What could go wrong: This is a small, completed trial with no phase designation, so results may not apply to everyone. The device may cause side effects like redness or scabbing, and long-term benefits are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PIGMENTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutis laxa severe cutaneous adverse reaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PIGMENTATION SKIN LAXITY SKIN SCARRING WRINKLE

Contacts and locations

Locations

AboutSkin Dermatology & DermSurgery

Greenwood Village, Colorado, 80111, United States
Boyd Beauty

Birmingham, Michigan, 48009, United States
Capital Laser & Skin Care

Chevy Chase, Maryland, 20815, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.